Literature DB >> 10725618

Low-grade MALT lymphoma of the stomach: a review of treatment options.

N R Schechter1, J Yahalom.   

Abstract

PURPOSE: Low-grade mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach (MLS) is often associated with the presence of Helicobacter pylori (H. pylori) bacteria. Eradication of the infection with antibiotic therapy may result in regression of the lymphoma. But when antibiotic treatment fails to reverse the malignant process or if H. pylori is absent, other treatment options should be considered. Because MLS is often confined to the stomach and regional lymph nodes, it is potentially curable with local therapy. Endoscopy and improved imaging, with endoscopic ultrasound (EUS) and computerized tomography (CT), have reduced the prior dependence on surgery for diagnosis and staging of gastric lymphomas. METHODS AND
RESULTS: This review details the advances in the diagnosis, classification, and imaging of MLS. We also describe the experience that supports the use of radiation therapy as the preferred treatment of MLS in patients who have not responded to antibiotic therapy or have not had evidence for H. pylori infection.
CONCLUSIONS: Radiation therapy for MLS is not only effective and safe, but offers the significant advantage of low morbidity and gastric function preservation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725618     DOI: 10.1016/s0360-3016(99)00522-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

Review 1.  Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management.

Authors:  M-Q Du; J C Atherton
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

Review 2.  Current status of gastric MALT lymphoma.

Authors:  T Wündisch; M Stolte
Journal:  Curr Gastroenterol Rep       Date:  2006-10

3.  Primary extranodal lymphomas of gastrointestinal localizations: a single institution 5-yr experience.

Authors:  B Mihaljević; R Nedeljkov-Jancić; V Vujicić; D Antić; S Janković; N Colović
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  Primary gastrointestinal non-Hodgkin's lymphoma: clinicopathological and prognostic analysis.

Authors:  Tong Wang; Wei Gui; Quanliang Shen
Journal:  Med Oncol       Date:  2009-06-30       Impact factor: 3.064

5.  Radiation therapy for gastric wall metastasis from esophageal carcinoma.

Authors:  Naoko Hashimoto; Jin Iwazawa; Hisashi Abe; Takashi Mitani; Kazufumi Kagawa
Journal:  Jpn J Radiol       Date:  2010-05-01       Impact factor: 2.374

6.  Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial.

Authors:  Agustin Avilés; María Jesús Nambo; Natividad Neri; Alejandra Talavera; Sergio Cleto
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 7.  Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Jeong Bae Park; Ja Seol Koo
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

8.  Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Sang-Won Kim; Do Hoon Lim; Yong Chan Ahn; Won Seog Kim; Seok Jin Kim; Young Hyeh Ko; Kyoung-Mee Kim
Journal:  World J Gastroenterol       Date:  2013-09-28       Impact factor: 5.742

Review 9.  Therapy of gastric mucosa associated lymphoid tissue lymphoma.

Authors:  Andrea Morgner; Renate Schmelz; Christian Thiede; Manfred Stolte; Stephan Miehlke
Journal:  World J Gastroenterol       Date:  2007-07-14       Impact factor: 5.742

10.  Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients.

Authors:  Joachim Yahalom; Amy J Xu; Ariela Noy; Stephanie Lobaugh; Monica Chelius; Karen Chau; Carol Portlock; Carla Hajj; Brandon S Imber; David J Straus; Craig H Moskowitz; Morton Coleman; Andrew D Zelenetz; Zhigang Zhang; Ahmet Dogan
Journal:  Blood Adv       Date:  2021-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.